J Garrett1, S Williams, C Wong, D Holdaway. 1. Department of Paediatrics and Child Health, Dunedin School of Medicine, University of Otago Medical School, New Zealand.
Abstract
OBJECTIVE: To investigate the efficacy of an increased dose of inhaled steroid used within the context of an asthma self management plan for treating exacerbations of asthma. DESIGN: Randomised, double blind, placebo controlled, crossover trial. METHODS:Twenty eight children aged 6-14 years with asthma of mild to moderate severity were studied for six months. Eighteen pairs of exacerbations were available for analysis, during which subjects took an increased dose of inhaled steroids or continued on the same dose. RESULTS: There was no significant difference between increasing inhaled steroids or placebo on morning or evening peak expiratory flow rates (PEFRs), diurnal peak flow variability, or symptom scores in the two weeks following an asthma exacerbation. Difference (95% confidence intervals) in baseline PEFR on days 1-3 were 3.4% (-3.5% to 10.4%) and -0.9% (-4.7% to 2.9%) for inhaled steroid and placebo, respectively. Spirometric function and the parents' opinion of the effectiveness of asthma medications at each exacerbation were also not significantly different between inhaled steroid or placebo. CONCLUSION: This study suggests that increasing the dose of inhaled steroids at the onset of an exacerbation of asthma is ineffective and should not be included in asthma self management plans.
RCT Entities:
OBJECTIVE: To investigate the efficacy of an increased dose of inhaled steroid used within the context of an asthma self management plan for treating exacerbations of asthma. DESIGN: Randomised, double blind, placebo controlled, crossover trial. METHODS: Twenty eight children aged 6-14 years with asthma of mild to moderate severity were studied for six months. Eighteen pairs of exacerbations were available for analysis, during which subjects took an increased dose of inhaled steroids or continued on the same dose. RESULTS: There was no significant difference between increasing inhaled steroids or placebo on morning or evening peak expiratory flow rates (PEFRs), diurnal peak flow variability, or symptom scores in the two weeks following an asthma exacerbation. Difference (95% confidence intervals) in baseline PEFR on days 1-3 were 3.4% (-3.5% to 10.4%) and -0.9% (-4.7% to 2.9%) for inhaled steroid and placebo, respectively. Spirometric function and the parents' opinion of the effectiveness of asthma medications at each exacerbation were also not significantly different between inhaled steroid or placebo. CONCLUSION: This study suggests that increasing the dose of inhaled steroids at the onset of an exacerbation of asthma is ineffective and should not be included in asthma self management plans.
Authors: I Charlton; A G Antoniou; J Atkinson; M J Campbell; E Chapman; T Mackintosh; D Schapira Journal: Arch Dis Child Date: 1994-04 Impact factor: 3.791
Authors: M Diane Lougheed; Catherine Lemiere; Francine M Ducharme; Chris Licskai; Sharon D Dell; Brian H Rowe; Mark Fitzgerald; Richard Leigh; Wade Watson; Louis-Philippe Boulet Journal: Can Respir J Date: 2012 Mar-Apr Impact factor: 2.409
Authors: Katherine Rivera-Spoljaric; Vernon M Chinchilli; Lindsay J Camera; Robert S Zeiger; Ian M Paul; Brenda R Phillips; Lynn M Taussig; Robert C Strunk; Leonard B Bacharier Journal: J Pediatr Date: 2009-03-25 Impact factor: 4.406